Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Tango Therapeutics Inc. — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.76 (market cap $7.97B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is far larger — about 2.1× Tango Therapeutics Inc.'s market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days and Tango Therapeutics Inc. for 0 Days on average.
| PDBC | TNGX | |
|---|---|---|
Market Cap | $7.97B | $3.74B |
Volume | 3,246,731 | 3,438,781 |
52-Week High | $20.10 | $32.90 |
52-Week Low | $13.19 | $7.50 |
Typical Hold Time | 56 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDBC, an ETF tracking diversified commodities, trades at $19.98, up 0.6% today, with a bullish technical signal from moving averages. The fund has delivered strong performance, rising 45.66% year-to-date through Q3 2026, driven by energy and agricultural gains amid geopolitical tensions. Short interest surged 215.4% in September 2026, indicating increased bearish speculation, while institutional investments from firms like Arlington Capital and Advisortrust Partners show confidence.
The outlook remains positive due to robust commodity trends, but risks include heightened short interest and geopolitical volatility. Investors benefit from broad commodity exposure without K-1 tax complexity, though price swings from supply shocks or economic shifts pose challenges. The fund's momentum and defensive appeal in uncertain markets support a favorable view, but monitoring short-term pressure is essential.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
